<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869943</url>
  </required_header>
  <id_info>
    <org_study_id>V3002401</org_study_id>
    <nct_id>NCT04869943</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer</brief_title>
  <acronym>ARTEST</acronym>
  <official_title>Randomized Phase 3 Efficacy Evaluation of Enobosarm Monotherapy vs Control Treatment of AR+/ER+/HER2- MBC in Patients With AR Nuclei Staining ≥40% Who Has Shown Disease Progression on a Nonsteroidal AI Fulvestrant and CDK 4/6 Inhibitor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veru Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veru Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+)&#xD;
      and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by&#xD;
      radiographic progression free survival (rPFS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety&#xD;
      study. Subjects will be randomized to the two treatment arms in a 1:1 fashion. The primary&#xD;
      efficacy endpoint of the study will be the median rPFS. Subjects will continue study&#xD;
      treatment until disease progression is observed or an unacceptable adverse event is observed.&#xD;
      A safety follow up visit will occur approximately 30 days after last dose of study drug.&#xD;
      Thereafter, survival follow up will completed monthly for one year. Survival follow up may be&#xD;
      completed by phone or records review. After one year, survival follow up will be completed&#xD;
      every 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. Subjects in the Control Treatment Group will receive a ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus or selective estrogen receptor modulator(SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the efficacy of Enobosarm in the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).</measure>
    <time_frame>Day 120</time_frame>
    <description>The primary endpoint for the study is the median radiographic progression free survival (rPFS) in the Enobosarm Treatment Group compared to the Control Treatment Group.&#xD;
Progression will be defined based on RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Day 180</time_frame>
    <description>Objective Response Rate (ORR), proportion of subjects with a best tumor response of ORR (PR or CR) on study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Enobosarm Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. The total duration of the study for a subject in the study from screening to follow-up visit is not standardized and will be different for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the Control Treatment Group will receive a ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enobosarm</intervention_name>
    <description>Oral Enobosarm 9mg per day</description>
    <arm_group_label>Enobosarm Treatment Group</arm_group_label>
    <other_name>VERU-024</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)</description>
    <arm_group_label>Control Treatment Group</arm_group_label>
    <other_name>Mestane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
          -  Be able to communicate effectively with the study personnel&#xD;
&#xD;
          -  Aged ≥18 years&#xD;
&#xD;
          -  For Female Subjects&#xD;
&#xD;
               -  Menopausal status&#xD;
&#xD;
          -  Be postmenopausal as defined by the National Comprehensive Cancer Network as either:&#xD;
&#xD;
               -  Age ≥55 years and one year or more of amenorrhea&#xD;
&#xD;
               -  Age &lt;55 years and one year or more of amenorrhea, with an estradiol assay &lt;20&#xD;
                  pg/mL&#xD;
&#xD;
               -  Age &lt;55 years and surgical menopause with bilateral oophorectomy&#xD;
&#xD;
          -  Be premenopausal or perimenopausal on ovarian suppression with LHRH agonist for at&#xD;
             least 4 months, with an estradiol assay &lt;20 pg/mL and a negative urine pregnancy test.&#xD;
&#xD;
          -  If subject is of child bearing potential, the subject must agree to use acceptable&#xD;
             methods of contraception:&#xD;
&#xD;
               -  If female study participant could become pregnant, use acceptable methods of&#xD;
                  contraception from the time of the first administration of study medication until&#xD;
                  6 months following administration of the last dose of study medication.&#xD;
                  Acceptable methods of contraception are as follows: Condom with spermicidal&#xD;
                  foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical&#xD;
                  sterilization of male partner (vasectomy with documentation of azoospermia) and a&#xD;
                  barrier method {condom used with spermicidal foam/gel/film/cream/suppository}&#xD;
&#xD;
               -  If female study participant has undergone documented tubal ligation (female&#xD;
                  sterilization), a barrier method (condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository) should also be used&#xD;
&#xD;
               -  If female study participant has undergone documented placement of an intrauterine&#xD;
                  device (IUD) or intrauterine system (IUS), a barrier method (condom with&#xD;
                  spermicidal foam/gel/film/cream/suppository) should also be used&#xD;
&#xD;
          -  For Male Subjects&#xD;
&#xD;
               -  Subject must agree to use acceptable methods of contraception:&#xD;
&#xD;
          -  If the study subject's partner could become pregnant, use acceptable methods of&#xD;
             contraception from the time of the first administration of study medication until 6&#xD;
             months following administration of the last dose of study medication. Acceptable&#xD;
             methods of contraception are as follows: Condom with spermicidal foam/gel/&#xD;
             film/cream/suppository [i.e., barrier method of contraception], surgical sterilization&#xD;
             (vasectomy with documentation of azoospermia) and a barrier method {condom used with&#xD;
             spermicidal foam/gel/film/cream/suppository}, the female partner uses oral&#xD;
             contraceptives (combination estrogen/progesterone pills), injectable progesterone or&#xD;
             subdermal implants and a barrier method (condom used with spermicidal&#xD;
             foam/gel/film/cream/suppository)&#xD;
&#xD;
          -  If female partner of a study subject has undergone documented tubal ligation (female&#xD;
             sterilization), a barrier method (condom used with spermicidal&#xD;
             foam/gel/film/cream/suppository) should also be used&#xD;
&#xD;
          -  If female partner of a study subject has undergone documented placement of an&#xD;
             intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with&#xD;
             spermicidal foam/gel/film/cream/suppository) should also be used&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2&#xD;
&#xD;
          -  Documented evidence of ER+/HER2- metastatic breast cancer&#xD;
&#xD;
          -  Measurable disease is required as per RECIST 1.1 (NOTE: Bone only metastatic disease&#xD;
             is acceptable but requires a measurable component&#xD;
&#xD;
          -  Have androgen receptor nuclei staining ≥40% as assessed by central laboratory&#xD;
&#xD;
          -  Received at least 2 prior lines of treatment in MBC setting which must have included&#xD;
             both an AI (monotherapy or combination) and fulvestrant (monotherapy or combination);&#xD;
             at least one must have been given in combination with a CDK 4/6 inhibitor.&#xD;
&#xD;
          -  Previously responded (without disease progression for at least 6 months) to one of the&#xD;
             following treatments: fulvestrant monotherapy or fulvestrant plus CDK 4/6 inhibitor or&#xD;
             nonsteroidal aromatase inhibitor monotherapy or nonsteroidal aromatase inhibitor plus&#xD;
             CDK 4/6 inhibitor for metastatic breast cancer.&#xD;
&#xD;
          -  Subject is willing to comply with the requirements of the protocol through the end of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to enobosarm&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5 X upper limit&#xD;
             of normal (ULN) or total bilirubin &gt;ULN (an elevated total bilirubin up to 1.5 X ULN&#xD;
             attributed to a previously confirmed diagnosis of Gilbert's disease is acceptable if&#xD;
             all other eligibility criteria are met). In patients with documented metastases to the&#xD;
             liver, the limits for inclusion are ALT or AST &gt;5.0 X ULN or total bilirubin &gt;1.5 X&#xD;
             ULN.&#xD;
&#xD;
          -  Patients with biliary catheter.&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min as measured using the Cockcoft Gault formula&#xD;
             (patients with mild and moderate renal failure are not excluded from participation in&#xD;
             this study)&#xD;
&#xD;
          -  Previously received &gt;1 course of systemic chemotherapy (not including immunotherapies&#xD;
             or targeted therapies) for the treatment of metastatic breast cancer.&#xD;
&#xD;
        Note: Subjects may have received 1 course of chemotherapy in the adjuvant or neoadjuvant&#xD;
        setting would not count as a line of therapy.&#xD;
&#xD;
          -  Subjects with radiographic evidence of central nervous system (CNS) metastases as&#xD;
             assessed by CT or MRI that are not well-controlled (symptomatic or requiring control&#xD;
             with continuous corticosteroid therapy [e.g., dexamethasone]) Note: Subjects with CNS&#xD;
             metastases are permitted to participate in the study if the CNS metastases are&#xD;
             medically well-controlled and stable for at least 30 days after receiving local&#xD;
             therapy (irradiation, surgery, etc.)&#xD;
&#xD;
          -  Radiotherapy within 14 days prior to randomization except in case of localized&#xD;
             radiotherapy for analgesic purpose or for lytic lesions at risk of fracture, which can&#xD;
             then be completed within 7 days prior to randomization. Subjects must have recovered&#xD;
             from radiotherapy toxicities prior to randomization&#xD;
&#xD;
          -  Any comorbid disease or condition (medical or surgical) which might compromise the&#xD;
             hematologic, cardiovascular, endocrine, pulmonary, severe renal impairment,&#xD;
             gastrointestinal, hepatic, or central nervous system; or other conditions that may&#xD;
             interfere with the absorption, distribution, metabolism or excretion of study drug, or&#xD;
             would place the subject at increased risk&#xD;
&#xD;
          -  Treatment with any investigational product within &lt; 4 half-lives for each individual&#xD;
             investigational product OR within 30 days prior to randomization&#xD;
&#xD;
          -  Major surgery within 30 days prior to randomization&#xD;
&#xD;
          -  Treatment with testosterone, methyltestosterone, oxandrolone (Oxandrin®),&#xD;
             oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such&#xD;
             as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including&#xD;
             herbals), or antiandrogens (enzalutamide, abiraterone, bicalutamide, apalutamide, or&#xD;
             darolutamide). Previous therapy with testosterone and testosterone-like agents is&#xD;
             acceptable with a 30-day washout (if previous testosterone therapy was long term depot&#xD;
             within the past 6 months, the site should contact the Medical Monitor) or any other&#xD;
             androgenic agent.&#xD;
&#xD;
          -  Treatment with any of the following hormone replacement therapies for metastatic&#xD;
             breast cancer. Prior use in the adjuvant or neoadjuvant setting is allowed if the&#xD;
             treatment is, discontinued greater than 30 days prior to randomization&#xD;
&#xD;
               -  Estrogens&#xD;
&#xD;
               -  Megesterol acetate&#xD;
&#xD;
               -  Testosterone&#xD;
&#xD;
          -  All other concurrent anticancer treatments (including, but not limited to, all SERMs&#xD;
             unless randomized to the Control Treatment Group with a SERM as the control treatment,&#xD;
             AIs unless randomized to Control Treatment Group (exemestane or exemestane plus&#xD;
             everolimus) with the AI containing treatment as the control treatment, and all CDK 4/6&#xD;
             inhibitors)&#xD;
&#xD;
          -  An abnormal ECG result which, based on the investigator's clinical judgment, would&#xD;
             place the subject at increased risk&#xD;
&#xD;
          -  Has a known additional, invasive, malignancy that is progressing or required active&#xD;
             treatment in the last 5 years [note: subjects with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, ductal breast carcinoma in situ, bladder cancer&#xD;
             (superficial treated), or cervical carcinoma in situ that have undergone potentially&#xD;
             curative therapy are not excluded]&#xD;
&#xD;
          -  Pregnant, lactating, or breastfeeding, or intending to become pregnant during the&#xD;
             study or within 60 days after the final dose of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barnette</last_name>
    <role>Study Chair</role>
    <affiliation>Veru Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barnette</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodriguez</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Oncology and Hematology, LLC.</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talia Wyckoff</last_name>
      <phone>907-257-9851</phone>
      <email>talia@alaskaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Steven Lui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Garcia</last_name>
      <phone>480-398-7671</phone>
      <email>andrea.garcia@ironwoodcrc.com</email>
    </contact>
    <investigator>
      <last_name>Sujith Kalmadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Health/ Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karol Banks</last_name>
      <phone>480-256-3333</phone>
      <email>Karolyn.banks@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Qing Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palo Verde Hematology Oncology</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deepak K Nayak</last_name>
      <phone>602-978-6255</phone>
      <email>dnayak@pvcancer.com</email>
    </contact>
    <investigator>
      <last_name>Amol Rakkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Insitute of Hope and Innovation</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>818-844-1678</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Paul La Porte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaime Chung</last_name>
      <phone>415-925-5040</phone>
      <email>JChang@marincancercare.com</email>
    </contact>
    <investigator>
      <last_name>Kristin Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Research Institute (CRI)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clare Gregorio</last_name>
      <phone>323-660-6200</phone>
      <email>cg@caresinst.com</email>
    </contact>
    <investigator>
      <last_name>Ghassan Al-Jazayrly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivy Wong</last_name>
      <phone>415-353-7873</phone>
      <email>Ivy.Wong@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Hope Rugo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Young</last_name>
      <phone>707-799-9443</phone>
      <email>Kimberly.Young@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Jarrod Holmes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Beland</last_name>
      <phone>303-285-5081</phone>
      <email>kelly.beland@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jenny Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Novella</last_name>
      <phone>239-938-9315</phone>
      <email>Rachel.Novella@usa.genesiscare.com</email>
    </contact>
    <investigator>
      <last_name>Mohammad Jahanzeb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital/ BayCare Health System, Inc</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Boyd</last_name>
      <phone>727-461-8519</phone>
      <email>Jennifer.Boyd@BayCare.org</email>
    </contact>
    <investigator>
      <last_name>Ben Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami- Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Onaidy T Torres</last_name>
      <phone>305-243-6823</phone>
      <email>otorres@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Elisa Krill Jackson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Lebron</last_name>
      <phone>786-527-8546</phone>
      <email>JacqueliLe@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Lauren Carcas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists, PA</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Bellamy</last_name>
      <phone>850-696-4423</phone>
      <email>lbellamy@woodlandsmed.com</email>
    </contact>
    <investigator>
      <last_name>Rami Owera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer &amp; Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamie Hodgsen</last_name>
      <phone>706-353-5000</phone>
      <email>jhodgson@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Gustavo Westin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blessing Corporate Services</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiley McGlauchlen</last_name>
      <phone>217-223-8400</phone>
      <phone_ext>7201</phone_ext>
      <email>Kiley.Mcglauchlen@blessinghealth.org</email>
    </contact>
    <investigator>
      <last_name>Kellie Flippin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa McCary</last_name>
      <phone>318-813-1465</phone>
      <email>lmccar@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Burton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute Breast Oncology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Ryabin</last_name>
      <phone>617-495-1000</phone>
      <email>Nicole_Ryabin@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Erica Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sikar Grewal</last_name>
      <phone>248-564-1485</phone>
      <email>grewal@rev-research.com</email>
    </contact>
    <investigator>
      <last_name>Savitha Balaraman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sikar Grewal</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sikar Grewal</last_name>
      <phone>248-564-1485</phone>
      <email>grewal@rev-research.com</email>
    </contact>
    <investigator>
      <last_name>Adil Akhtar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center- Mosaic Life Care Cancer Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trisha England</last_name>
      <phone>816-271-7937</phone>
      <email>trisha.england2@mymlc.com</email>
    </contact>
    <investigator>
      <last_name>Gopichand Pendurti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trisha Vincent</last_name>
      <phone>702-952-3400</phone>
      <email>trisha.vincent@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Liawaty Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astera Cancer Care</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Percy Yeung</last_name>
      <phone>732-390-7750</phone>
      <email>percy.yeung@asterahealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Bruno Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Medical Center Mullica Hill</name>
      <address>
        <city>Mullica Hill</city>
        <state>New Jersey</state>
        <zip>08062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Abate</last_name>
      <phone>856-508-2119</phone>
      <email>AbateS@ihn.org</email>
    </contact>
    <investigator>
      <last_name>Erev Tubb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Medical Center</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Abate</last_name>
      <phone>856-641-7526</phone>
      <email>AbateS@ihn.org</email>
    </contact>
    <investigator>
      <last_name>Mylene Go</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Reilly</last_name>
      <phone>513-585-2165</phone>
      <email>Susan.Reilly@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Gina Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Viviani</last_name>
      <phone>216-444-9649</phone>
      <email>VIVIANS@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Halle Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romenta Pollard</last_name>
      <phone>412-641-5430</phone>
      <email>pollardrr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Brufsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Heimann</last_name>
      <phone>402-334-6113</phone>
      <email>kheimann@gucancer.com</email>
    </contact>
    <investigator>
      <last_name>Robert D Schumaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Clinical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>38102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Stewart</last_name>
      <phone>901-226-1471</phone>
      <email>Tracy.Stewart2@BMHCC.org</email>
    </contact>
    <investigator>
      <last_name>Phillip Lammers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-579-9800</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <phone>703-280-5390</phone>
      <email>marci.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anne Favret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendi Gobhardt</last_name>
      <phone>757-466-8663</phone>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Danso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <phone>276-228-7665</phone>
      <email>natasha.holt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Amanda Gillespie-Twardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research and Innovation</name>
      <address>
        <city>Puyallup</city>
        <state>Washington</state>
        <zip>98372</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Wahinekapu</last_name>
      <phone>253-697-1310</phone>
      <email>dwahinekapu@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Meghana Bansal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenna Olyanich</last_name>
      <phone>206-606-2053</phone>
      <email>bozhena5@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Hannah Linden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Giachetti</last_name>
      <phone>509-228-1684</phone>
      <email>Bethany.giachetti@ccnw.net</email>
    </contact>
    <investigator>
      <last_name>Kristine Rinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Aneta Dobrzyńska-Rutkowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Szpital Onkologiczny NU-MED</name>
      <address>
        <city>Maków Mazowiecki</city>
        <zip>97-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beata Glogowska</last_name>
      <phone>4844 7868160</phone>
      <email>beata.glogowska@nu-med.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Chmielowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Oddział Onkologii Klinicznej i Chemioterapii Europejskie Centrum Zdrowia Otwock&quot;</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Jackiewicz-Papierowska</last_name>
      <phone>+48 22 710 30 25</phone>
      <email>marta.jackiewicz-papierowska@ecz-otwock.pl</email>
    </contact>
    <investigator>
      <last_name>Cezary Szczylik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elżbieta Sierkowska</last_name>
      <phone>+48 509761001</phone>
      <email>Elzbieta.Sierkowska@pib-nio.pl</email>
    </contact>
    <investigator>
      <last_name>Zbigniew Nowecki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Grubiak</last_name>
      <phone>48 792206646</phone>
      <email>grubiak.marta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ewa Kalinka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzka Przychodnia Onkologiczna, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi</name>
      <address>
        <city>Łódź</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Wlodarczyk</last_name>
      <phone>48 426895669</phone>
      <email>wlodarczykannna@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Monika Kukulska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrative Optimal Health of Puerto Rico, New Alliance Integrative Research / Puerto Rico Consortium for Clinical Investigation, INC</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Rodriguez-Zayas</last_name>
      <phone>(787) 523-5876</phone>
      <email>jose.rodriguez@prcci.org</email>
    </contact>
    <investigator>
      <last_name>Raul Morales-Borges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A Coruña University Hospital</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Barbeito Gomez</last_name>
      <phone>34-93-248-3137</phone>
      <email>Maria.Barbeito.Gomez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Silvia Antolín Novoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia (ICO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Feliu</last_name>
      <phone>34-90-232-22-33</phone>
      <email>cfeliu@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Juan Miguel Gil Gil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Garcia</last_name>
      <phone>34-91-756-79-84</phone>
      <phone_ext>4817</phone_ext>
      <email>mgarcia@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Beatriz Rojas Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia (CHUV)</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Coret</last_name>
      <phone>34-91-336-80-00</phone>
      <email>silviacoret@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Begoña Bermejo De Las Heras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Dnipropetrovsk City Multi-field Clinical Hospital #4&quot;, Dnepropetrovsk state m</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nataliia Urzhumova</last_name>
      <phone>38 097 322 27 44</phone>
      <email>ntlurzhumova@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Igor Bondarenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State institution &quot;V.T. Zaycev Institute of general and urgent surgery of National academy medical sciences of Ukraine&quot;</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmytro Piliuhin</last_name>
      <phone>38 050 979 98 84</phone>
      <email>Trials.kh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Oleksandr Dudnichenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Khmelnytsky Regional Antitumor Center, Department of Breast, Skin, Soft Tissues and Bones Tumorsa</name>
      <address>
        <city>Khmelnytskyi</city>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ganna Drobner</last_name>
      <phone>'095 610 80 00</phone>
      <email>adrobneri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Igor Drobner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncology Center</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Natalia Voitko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Oncological Dispensary</name>
      <address>
        <city>Odessa</city>
        <zip>65000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dmytro Trukhin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

